Insights

Innovative CNS Focus Autobahn Therapeutics specializes in developing regenerative therapies for CNS disorders, targeting high unmet needs such as neuropsychiatry, neurodegeneration, and neuroinflammation. This presents opportunities to connect with healthcare providers and institutions focused on advanced neurotherapies and specialized CNS treatments.

Strong Funding & Growth With recent financing of $100 million and a revenue range of $10 to 25 million, Autobahn is well-capitalized for expansion and clinical development. This indicates a growing pipeline and potential for partnerships, licensing deals, or investments in complementary biotech innovations.

Advanced Drug Pipeline The lead candidate, ABX-002, has received Orphan Drug Designation and is in clinical development, showcasing promising progress. There is an opportunity to collaborate or offer services related to clinical trial support, biomarker discovery, and regulatory consulting within the CNS space.

Technologically Driven Autobahn leverages a sophisticated platform that combines validated biology with brain-targeting chemistry, indicating a focus on cutting-edge research tools and collaborations. Companies providing advanced research technologies, data analytics, or specialized lab services could position themselves as valuable partners for Autobahn’s R&D efforts.

Autobahn Therapeutics, Inc. Tech Stack

Autobahn Therapeutics, Inc. uses 8 technology products and services including Site Kit, Babel, core-js, and more. Explore Autobahn Therapeutics, Inc.'s tech stack below.

  • Site Kit
    Analytics
  • Babel
    Development
  • core-js
    Javascript Libraries
  • WP Engine
    Platform As A Service
  • PHP
    Programming Languages
  • Google Tag Manager
    Tag Management
  • GoDaddy
    Web Hosting
  • Nginx
    Web Servers

Autobahn Therapeutics, Inc.'s Email Address Formats

Autobahn Therapeutics, Inc. uses at least 1 format(s):
Autobahn Therapeutics, Inc. Email FormatsExamplePercentage
FLast@autobahntx.comJDoe@autobahntx.com
48%
Last@autobahntx.comDoe@autobahntx.com
2%
FLast@autobahntx.comJDoe@autobahntx.com
48%
Last@autobahntx.comDoe@autobahntx.com
2%

Frequently Asked Questions

Where is Autobahn Therapeutics, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Autobahn Therapeutics, Inc.'s main headquarters is located at 9880 Campus Point Drive, Suite 440. The company has employees across 2 continents, including North AmericaOceania.

What is Autobahn Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Autobahn Therapeutics, Inc.'s official website is autobahntx.com and has social profiles on LinkedInCrunchbase.

What is Autobahn Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Autobahn Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Autobahn Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, Autobahn Therapeutics, Inc. has approximately 32 employees across 2 continents, including North AmericaOceania. Key team members include General Counsel & Svp, Administration: J. B.Associate Director Clinical Operations: R. G.Director Clinical Operations: A. H.. Explore Autobahn Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Autobahn Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Autobahn Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Autobahn Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Autobahn Therapeutics, Inc.'s tech stack includes Site KitBabelcore-jsWP EnginePHPGoogle Tag ManagerGoDaddyNginx.

What is Autobahn Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Autobahn Therapeutics, Inc.'s email format typically follows the pattern of FLast@autobahntx.com. Find more Autobahn Therapeutics, Inc. email formats with LeadIQ.

How much funding has Autobahn Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2025, Autobahn Therapeutics, Inc. has raised $100M in funding. The last funding round occurred on Jul 24, 2024 for $100M.

When was Autobahn Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Autobahn Therapeutics, Inc. was founded in 2017.

Autobahn Therapeutics, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.

CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.

We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. 

Want to join our team? Please see our open positions on the Careers page of the Autobahn website: https://autobahntx.com/careers/

Section iconCompany Overview

Headquarters
9880 Campus Point Drive, Suite 440
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $100M

    Autobahn Therapeutics, Inc. has raised a total of $100M of funding over 3 rounds. Their latest funding round was raised on Jul 24, 2024 in the amount of $100M.

  • $10M$25M

    Autobahn Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $100M

    Autobahn Therapeutics, Inc. has raised a total of $100M of funding over 3 rounds. Their latest funding round was raised on Jul 24, 2024 in the amount of $100M.

  • $10M$25M

    Autobahn Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.